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ABSTRACT:

Purpose of Review: The intestinal allograft, with an enormous lymphoid load, is a highly
immunogenic organ which elicits a strong alloimmune response. In the early post transplant
period, a robust graft biopsy protocol via a temporary ileostomy is utilized for surveillance to
detect rejection. In the later post-transplant period, after enteral continuity is re-established,
graft biopsies via a colonoscopy become more cumbersome. Alternative methods for
intestinal allograft monitoring other than graft biopsy are of particular interest.
Recent Findings: Biomarkers and diagnostic tools such as Granzyme B, Perforin, fecal
Calprotectin, Citrulline, donor specific antibody (DSA), and zoom video-endoscopy have all
been studied for application as reliable methods of performing intestinal allograft
surveillance. Each modality has the capability of monitoring a separate and unique process in
the host-allograft immune response.
Summary: The goal to find a reliable , reproducible and non-invasive method for intestinal
graft monitoring remains an elusive one. Many of the current modalities available only serve
to act as complementary tests in conjunction with astute clinical observations. Graft biopsy
remains the gold standard for monitoring the intestinal allograft.
KEY POINTS:


Long-term outcome after intestinal transplantation is still negatively affected by
rejection



Better graft monitoring , other than biopsy, could reduce late allograft loss



Video-endoscopy is a reliable diagnostic tool but in expert hands



Molecules such as Granzyme B and Perforin, Citrulline or Calprotectin so far have
shown questionable results in allograft surveillance



DSAs are promising biomarkers but their management in clinical practice has still to be
clarified

INTRODUCTION:
Intestinal transplantation (ITx) has shown steady improvements in graft and patient survival
over the past 20 years, particularly with short-term results. Lasting improvements in longterm outcome, however, still remain a challenge. Late allograft loss due to acute rejection (AR)
still remains a vexing problem, in particular due to the challenge of diagnosing AR in a stable
recipient long removed from an aggressive, biopsy-driven, early post-transplant monitoring
protocol. Biopsy is the gold standard for the diagnosis of ITx allograft pathology. Currently we
lack a reliable biomarker able to forewarn of rejection episodes: we herein review recently
published data of non-invasive allograft monitoring after ITx.
MONITORING OF THE IMMUNE SYSTEM:
In kidney or liver transplant, blood tests such as creatinine level or liver function tests are
suitable to determine if there is graft dysfunction: such a simple and reproducible biomarker
has yet to be discovered in ITx. Currently, ITx monitoring is based on protocol biopsies.
However, this is an invasive procedure which requires a skilled operator as well as an
experienced histopathologist. An ideal biomarker should be non-invasive, reproducible, and
with a rapid result allowing for the initiation of prompt treatment.
-

Granzyme B and Perforin :

Similarly to kidney transplantation, the Bologna group (1-4) analyzed the blood expression of
Granzyme B (GB) and Perforin (PF) after ITx by real time polymerase chain reaction (PCR) on
32 recipients (494 blood samples) during episodes of AR, Epstein-Barr virus (EBV) or
cytomegalovirus (CMV) infection, and post-transplant lymphoproliferative disease (PTLD).
Both GB and PF are expressed in natural killer cells and cytotoxic T lymphocytes, acting as
effector molecules for the induction of apoptosis in target cells. The inability to use the test in

the first 28 days because of variable expression was a limiting factor. Mean levels of GB and
PF in the AR (GB=279.7; PF=256.7), PTLD (GB=199; PF=185.9), EBV (GB=133.2; PF=143.7),
and CMV (GB=151.3; PF=144) groups were significantly higher than in the normal group
(GB=100.1; PF=101.1) (all P<0.05, except for PF in CMV infection). Although the best accuracy
was obtained for the diagnosis of AR, half of the samples were eliminated due to confounding
conditions, limiting the clinical applicability. Sensitivity and specificity were 80% and 79% for
GB and 70% and 79% for PF, respectively, and the area under the receiver-operator
characteristics (ROC) curve was 0.87 for GB and 0.82 for PF. GB and PF levels rose in only 10
of 30 episodes of rejection from eight patients at a mean of 14 days (range 3–38) prior to AR.
Their conclusion was that GB and PF are diagnostic markers of AR even though the levels also
increase in case of viral infections or PTLD. GB and PF might act as predictive molecules but
should be interpreted in a clinical, histological and virological context. Therefore, their utility
is questionable.
-

Fecal Calprotectin:

Fecal Calprotectin have been widely correlated with inflammatory bowel disease activity,
proposing it as potential marker of ITx rejection. In an early Omaha study, fecal Calprotectin
levels were measured from ileostomy of 68 recipients with AR (n =12), viral enteritis (n= 5),
and nonspecific inflammation (n =16), and compared with 35 normal controls (5). During AR
episodes, fecal Calprotectin was significantly higher than in viral enteritis or normal controls
(198 mg/kg compared with 7 and 19 mg/kg, respectively (P = 0.0002)), and the cut-off level
was 92 mg/kg with specificity of 77% and sensitivity of 83%, as suggested by receiver
operator characteristics (ROC). In a follow-up study by the same group, published in 2011 (67), 732 stool samples were collected from 72 recipients: due to significant inter-patient
variability, defining an effective general “cutoff” level was difficult and not clinically
applicable. A Miami study (8) measured fecal Calprotectin on 29 recipients and a cut-off level
of 100 ng/mg was considered positive. Retrospective evaluation of 122 samples revealed nonspecific results. The assay was sensitive to the identification of intestinal illnesses in general,
but not useful in specifically distinguishing AR from these ongoing organic intestinal
problems. Finally a report from Argentina (9) showed a good sensitivity but low specificity
for the diagnosis of intestinal AR. High Calprotectin levels were also observed in other clinical
conditions. In summary, a clear role for Calprotectin as a marker of rejection has yet to be
realized.

-

Citrulline:

Serum Citrulline is a non-protein amino acid deriving from glutamine conversion within
enterocytes, studied as a marker of functional enterocyte mass in short bowel syndrome. The
Miami group (10-14) analyzed 2135 dried blood spots from 57 intestinal transplant
recipients at or beyond 3 months post-transplant. Lower Citrulline levels were found in
presence of mild, moderate, or severe AR, bacteremia or respiratory infection, in the pediatric
age group, and were dependent upon the time from transplant. Using a <13 vs. =/>13
µmoles/L as a cutoff point, levels =/>13 µmoles/L were associated with moderate or severe
rejection. They confirmed their data in 2012 (15), concluding that Citrulline in ITx may serve
as a non invasive biomarker with excellent negative predictive values in the long term followup of pediatric recipients. On the contrary, a New York study (16-18) reported that Citrulline
reflects the extent of mucosal injury regardless of the etiology, but does not seem to be a
predictive marker for rejection or viral enteritis, as its values may decline only when diffuse
mucosal damage has occurred. These last results were confirmed by a Madrid group (19):
they reported Citrulline as a sensitive and specific biomarker of the residual functional
enterocyte load, related to enteric feeding tolerance, but its prognostic value as a rejection
marker was questionable. Recently, a Bologna study (20) investigated Citrulline according to
time from ITx, episodes of AR and creatinine clearance. Twenty-four adult recipients were
prospectively studied. The results were compared with those of 19 healthy controls and of 29
patients with chronic renal failure. Citrulline sensitivity and specificity in detecting AR after
the 45th post-operative day were 38% and 83% using Citrulline threshold observed in healthy
controls, and 69% and 77% using Citrulline threshold adjusted for chronic renal failure
degree. Their conclusion was that adjusting Citrulline threshold for chronic renal failure
degree almost doubled the sensitivity of Citrulline as a non-invasive marker of AR in ITx.
Summarizing the reported studies, Citrulline probably expresses an exclusionary role because
its higher levels are unlikely correlated with severe AR, and its major limitation is a lack of
forewarning of AR episodes.
-

Donor Specific Antibodies:

Donor specific antibodies (DSAs) represent the humoral alloimmunity against donor antigens:
it has been widely established in other solid organ transplants that DSAs contribute to
rejection and late allograft loss. After ITx, pre-transplant (pre-formed) DSAs are present in

nearly one-third of patients and post-transplant (de novo) DSAs develop in up to 40% of
recipients. Recent literature shows that pre-formed and/or de novo DSAs are correlated with
ITx rejection and allograft loss. A Pittsburgh report in 2000 (21) addressed the impact of
DSAs, reporting that a positive T-cell lymphocytotoxic cross-match increases the frequency
and severity of rejection after ITx, particularly with isolated bowel graft. In 2010, the Los
Angeles group (22) showed that DSAs were associated with higher allograft loss and
mortality while a Miami study (23) correlated DSAs with more frequent and severe episodes
of rejection (P=0.041). In the Miami report DSAs were pre-formed (n=5, anti-human leukocyte
antigen class II=3, anti-class I and II=2), de novo (n=4, 15.25±4.72 days after transplantation,
anti-class II=1, and anti-class I and II=3) and never (n=6). Among 63 biopsies, 30 (47.6%) had
significant correlations with positive DSA (kappa=0.30, P<0.001) and manifested severe
rejection grade (P=0.009). In 2012, a Pittsburgh study (24) analyzed 194 primary adult
recipients: complement-dependent lymphocytotoxic cross-match (CDC-XM) was positive in
55 (28%). HLA-DSA was detectable before transplant in 49 (31%) recipients with 19
continuing to have circulating antibodies. Another 19 (18%) developed de novo DSAs. Ninety
percent of patients with pre-formed DSAs harbored HLA Class-I, whereas 74% of recipients
with de novo antibodies had Class-II. Most antibody-mediated rejection (AMR) cases occurred
in the first 3 months after transplant and patients with persistent DSAs exhibited the highest
risk of AMR. Pre-formed DSAs significantly (p < 0.05) increased the risk of AR. Persistent and
de novo HLA-DSA significantly (p < 0.001) increased risk of chronic rejection and associated
graft loss. Inclusion of the liver was a significant predictor of better outcome (p = 0.004, HR =
0.347) with significant clearance of pre-formed antibodies (p = 0.04, OR = 56) and lower
induction of de novo DSAs (p = 0.07, OR = 24). The Berlin group (25) recently confirmed that
the development of de novo DSAs following ITx is often associated with AR, observing that the
number of mismatched antigens and epitopes correlates with the probability of developing de
novo DSAs. Different results were shown in a 2013 study by the Indianapolis group (26): of
131 intestinal/multivisceral transplants, 27 (21%) had a positive flow cytometry cross-match
(FCXM). Positive cross-match was not associated with an increased incidence of AR and graft
loss (30% and 37% vs. 29% and 47%; P=0.94 and 0.35, respectively). This effect was
maintained in liver-excluding transplants. The authors attributed their positive outcome to
the immunosuppressive regimen based on induction by thymoglobulin and rituximab, and
maintenance with tacrolimus and prednisone plus monthly doses of anti-interleukin-2
receptor antibody (IL-2RA) for the recipients of liver-free allografts. However, cross-matching
patients was based on the less sensitive FCXM assay compared to a Luminex-based assay, thus

may be underestimating the impact of DSAs (23). The virtual cross-match (VXM), in which
known recipient HLA antibodies are prospectively compared to donor HLA type, provides one
mean to optimize organ allocation and minimize immunologic risk. In fact, the VXM was
recently shown (27) by the Washington DC group to allow for successful isolated ITx with
acceptable short-term outcomes in sensitized patients. A number of papers have been
presented at the recent Intestinal Small Bowel Transplant Symposium (ISBTS) held in June
2015 in Argentina. A Los Angeles report (28) confirmed that the presence of pre-formed or de
novo DSAs leads to inferior survival outcomes following ITx. A study from the Washington DC
group (29) showed that the development of de novo DSAs occurs at a rapid and high
incidence after ITx. Their monitoring included weekly DSA analysis for 2 months, then
monthly testing for the remaining year. If de novo DSAs appeared, then weekly monitoring
was reinstituted. De novo DSAs developed in 32% recipients at a median time of 22.5 days
after transplant. Liver inclusion was not associated with any difference in the development of
de novo DSAs (p =0. 21) as confirmed by another paper from the Palo Alto group (30). The
Indiana team also performed DSA monitoring and noted that the development of de novo DSA
had a trend towards the development of chronic rejection (14% vs 5%, p = 0.21) and graft
loss due to AR (18% vs 7%, p= 0.14) (31). Boluda et al. from Madrid (32) showed that the
presence of DSAs is linked to re-transplantation, being unusual in candidates for first
transplant. In summary, there is still some debate going on regarding the impact of DSAs and
its use as an ITx graft monitoring tool, but a large amount of evidence shows that the presence
of de novo or pre-formed DSAs is involved negatively in long-term graft survival. New
therapeutic strategies have been developed in recent years (33-36) to treat DSAs, but their
description is beyond the scope of the present review.
VISUAL MONITORING OF THE GRAFT:
Visual graft surveillance is the easiest one over other forms of monitoring after solid organ
transplantation, due to the graft ileostomy manufactured for biopsy. Ideally, endoscopy itself
through the ileostomy (or, when the stoma has been taken down, a gastroscopy or
colonoscopy) should be able to monitor the graft, avoiding the more invasive biopsy
procedure with the possible hazards of mucosal hematomas, bleeding and perforations,
especially in small and/or friable grafts. The Pittsburgh group examined (37) this issue,
documenting that endoscopy alone would have missed 37% of cases of AR in 1273
endoscopies performed in 41 children. In their initial study they used fiber-optic endoscopy,

but 8 years later (38), with the improved magnification and optical resolution, new video
endoscopes have shown advantages of modern technology in detecting AR after ITx.

-

Zoom Videoendoscopy:

In 2006, the Miami group (38) analyzed the video-endoscopic diagnosis of rejection,
comparing it to histological findings. Adult patients showed a sensitivity of 45%, a specificity
of 98%, a positive predictive value of 82%, and a negative predictive value of 88%. The most
intriguing aspect of this study was that, on 59 distinct occasions in which the results were
endoscopy-negative but biopsy-positive for AR, rejections were not treated on the basis of
clinical evaluation and 58 (98%) resolved without further therapy. More recently a Bologna
study (39-40) evaluated 52 protocol endoscopies over a period of 2 years on 17 adult
recipients with more than 5 years follow-up. All the 52 endoscopic findings were comparable
to biopsy-definitive results (specificity was 98%): only 1 case of mild enteritis and 1 case of
EBV chronic infection at biopsy were not diagnosed by endoscopy, while no episodes of
rejection were diagnosed either by biopsy or endoscopy because the study group was
represented by stable recipients in long-term follow-up. Conversely, the Pittsburgh group in
2012 (41) reported different results, analyzing a number of adult endoscopies performed in
66 asymptomatic ‘‘surveillance’’ recipients and 71 symptomatic recipients. For surveillance
patients, 125 ileoscopies were performed to collect 590 biopsies, and for the symptomatic
group 229 ileoscopies and jejunoscopies were conducted to obtain 434 biopsies. The
sensitivity and specificity of endoscopic visualization in detecting AR was 50% and 91.5% for
the surveillance group and 43% and 67% for the symptomatic patients respectively. In
surveillance, visual impression alone would have missed three cases of moderate and no cases
of severe AR, while in the symptomatic group visual inspection alone would have missed 20
cases of moderate AR. Their conclusion was that in symptomatic patients, visual inspection
detected all cases of severe rejection but would have missed patients with early readily
treatable rejection, supporting the current clinical practice of ileoscopic biopsy for graft
surveillance in asymptomatic patients.

CONCLUSION:
In conclusion, over the last 15 years there have been many attempts to find an alternative to
biopsy for prevention and/or diagnosis of AR, in order to improve long-term graft survival
after intestinal transplantation (Table 1). Serum or fecal biomarkers (Granzyme B and
Perforin, Citrulline, Calprotectin) have been analyzed by many groups and, although
promising to monitor the immune system, so far they have missed their role substituting the
gold standard biopsy. Recently, DSAs have shown a link to graft survival, but their clinical
significance in a day-by-day laboratory monitoring is still far from being fully understood.
Zoom video-endoscopy has been identified as a useful tool to support biopsy findings, but its
exclusionary role as non-invasive marker of the intestinal graft probably requires technology
innovations still not available on the scientific market.

REFERENCES and RECCOMENDED READING :
Papers of particular interest, published within the period of review, have been highlighted as:
* of special interest
** of outstanding interest
1. D’Errico A, Corti B, Pinna AD, et al.: “Granzyme B and perforin as predictive markers for
acute rejection in human intestinal transplantation.” Transplant Proc 2003; 35:3061–3065.
2. Corti B, Altimari A, Gabusi E, et al.: “Potential of real-time PCR assessment of granzyme
B and perforin up-regulation for rejection monitoring in intestinal transplant recipients.”
Transplant Proc 2005; 37:4467–4471.
3. Corti B, Altimari A, Gabusi E, et al.: “Two years’ experience of acute rejection
monitoring of intestinal transplant recipients by real-time PCR assessment of granzyme B and
perforin up-regulation: considerations on diagnostic accuracy.” Transplant Proc 2006;
38:1726–1727.
4. Altimari A, Gruppioni E, Capizzi E, et al.: “Blood monitoring of granzyme B and perforin
expression

after

intestinal

transplantation:

Transplantation 2008; 85:1778–1783.

considerations

on

clinical

relevance.”

5. Sudan D, Vargas L, Sun Y, et al.: “Calprotectin: a novel noninvasive marker for intestinal
allograft monitoring.” Ann Surg 2007; 246:311–315.
6. Mercer DF : “Hot topics in postsmall bowel transplantation: noninvasive graft
monitoring including stool calprotectin and plasma citrulline.” Curr Opin Organ Transplant
2011; 16:316–322.
7. Mercer DF, Vargas L, Sun Y, et al.: “Stool Calprotectin Monitoring After Small Intestine
Transplantation.” Transplantation 2011;91: 1166–1171.
8. Akpinar E, Vargas J, Kato T, et al.: “Fecal calprotectin level measurements in small
bowel allograft monitoring: a pilot study.” Transplantation 2008; 85:1281– 1286.
9. Cagnola H, Scaravonati R, Cabanne A, et al.: “Evaluation of calprotectin level in
intestinal content as an early marker for graft rejection.” Transplant Proc 2010; 42:57–61.
10.

Pappas PA, Saudubray JM, Tzakis AG, et al.: “Serum citrulline and rejection in

small bowel transplantation: a preliminary report.” Transplantation 2001; 72:1212–1216.
11.

Pappas PA, Tzakis G, Gaynor JJ, et al.: “An analysis of the association between

serum citrulline and acute rejection among 26 recipients of intestinal transplant.” Am J
Transplant 2004; 4:1124–1132.
12.

Yu HC, Tuteja S, Moon JI, et al.: “Utilization of dried blood spot citrulline level as

a noninvasive method for monitoring graft function following intestinal transplantation.”
Transplantation. 2005 ;80:1729-1733.
13.

David AI, Selvaggi G, Ruiz P, et al.: “Blood citrulline level is an exclusionary

marker for significant acute rejection after intestinal transplantation.” Transplantation
2007; 84:1077–1081.
14.

Ruiz P, Tryphonopoulos P, Island E, et al.: “Citrulline evaluation in bowel

transplantation.” Transplant Proc 2010; 42:54–56.

15.

Hibi T, Nishida S, Garcia J, et al.: “Citrulline level is a potent indicator of acute

rejection in the long term following pediatric intestinal/multivisceral transplantation.” Am J
Transplant. 2012 ;12 Suppl 4:S27-32.
16.

Gondolesi G, Fishbein T, Chehade M, et al.: “Serum citrulline is a potential

marker for rejection of intestinal allografts.” Transplant Proc 2002; 34:918–920.
17.

Gondolesi GE, Kaufman SS, Sansaricq C, et al.: “Defining normal plasma citrulline

in intestinal transplant recipients.” Am J Transplant 2004; 4:414–418.
18. Gondolesi G, Ghirardo S, Raymond K, et al. : “The value of plasma citrulline to predict
mucosal injury in intestinal allografts.” Am J Transplant 2006; 6:2786– 2790.
19. Vecino López R, Andrés Moreno AM, Ramos Boluda E , et al.: “Plasma citrulline
concentration as a biomarker of intestinal function in short bowel syndrome and in intestinal
transplant [Article in Spanish]” . An Pediatr (Barc). 2013 ;79:218-23.
20. Pironi L, Guidetti M, Lauro A et al.: “Plasma citrulline after small bowel
transplantation: effect of time from transplantation, acute cellular rejection and renal failure.”
Clin Transplant. 2015 Sep 11. doi: 10.1111/ctr.12630. [Epub ahead of print]
21. Bond G, Reyes J, Mazariegos G, et al.: “The impact of positive T-cell lymphocytotoxic
crossmatch on intestinal allograft rejection and survival.” Transplant Proc 2000; 32:1197–
1198.
22. Farmer DG, Venick RS, Colangelo J, et al. : “Pretransplant predictors of survival after
intestinal transplantation: analysis of a single-center experience of more than 100
transplants.” Transplantation 2010; 90:1574–1580.
23. Tsai HL, Island ER, Chang JW, et al.: “Association between donor-specific antibodies
and acute rejection and resolution in small bowel and multivisceral transplantation.”
Transplantation 2011; 92:709–715.

24. Abu-Elmagd KM, Wu G, Costa G, et al.: “Preformed and de novo donor specific
antibodies in visceral transplantation: long-term outcome with special reference to the liver.”
Am J Transplant 2012; 12:3047–3060.
25.

Gerlach UA, Lachmann N, Sawitzki B, et al.: “Clinical relevance of the de novo

production of anti-HLA antibodies following intestinal and multivisceral transplantation.”
Transpl Int 2014; 27:280–289.
** A 10 year experience evaluating the incidence and characteristics of de novo donor
specific antibody in intestinal transplantation.
26.

Kubal CA, Mangus RS, Vianna RM, et al.: “Impact of positive flow cytometry

crossmatch on outcomes of intestinal/multivisceral transplantation: role anti- IL-2 receptor
antibody.” Transplantation 2013; 95:1160–1166.
27. Hawksworth JS, Rosen-Bronson S, Island E, et al.: “Successful isolated intestinal
transplantation in sensitized recipients with the use of virtual crossmatching.” Am J
Transplant 2012; 12 (Suppl 4):S33–S42.
28. Cheng EY, Wozniak LJ, Venick RS, et al. : “Clinical Impact of Donor-Specific Antibodies
on Intestinal Allograft Rejection and Survival.” Paper presented at the XIV International
Small Bowel Transplant Symposium, Buenos Aires, Argentina, 2015.
29. Matsumoto CS, Hawksworth J, Kozlowski S, et al.: “Incidence and Timing of Denovo
Donor Specific Antibody in Intestinal Transplantation.” Paper presented at the XIV
International Small Bowel Transplant Symposium, Buenos Aires, Argentina, 2015.
30. Pham T, Castillo RO, Concepcion W, et al.: “Donor Specific Antibodies Are Associated
with Rejection After Small Bowel and Multi-Visceral Transplant in Children.” Paper presented
at the XIV International Small Bowel Transplant Symposium, Buenos Aires, Argentina,
2015.
31. Kubal, C, Mangus, R, Saxena R, et al.: “Prospective Monitoring of Donor-specific AntiHLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo
Antibodies.” Transplantation 2015; 99: e49-e56

** Prospective monitoring of DSA post transplant and outcomes associated with the
development of de novo DSA.
32. Boluda ER, Moreno AA, Molina Arias M, et al.: “Anti-HLA Antibodies and Rejection in
Pediatric Intestinal Transplantation.” Paper presented at the XIV International Small Bowel
Transplant Symposium, Buenos Aires, Argentina, 2015.
33.

Kaneku H, Wozniak LJ: “Donor-specific human leukocyte antigen antibodies in

intestinal transplantation.” Curr Opin Organ Transplant 2014; 19:261–266.
34. Khanna A, Zhang A, Diaz G, et al.: “Visceral transplantation in highly sensitized
patients” Paper presented at the XIV International Small Bowel Transplant Symposium,
Buenos Aires, Argentina, 2015.
35. Segovia MC, Kazimi MM, Skorupski SM, et al.: “Intestine transplantation across a
positive crossmatch with preformed donor specific antibodies-a single center experience.”
Paper presented at the XIV International Small Bowel Transplant Symposium, Buenos
Aires, Argentina, 2015.
36.

Iyer K, Templeton A, Chamberlain C, et al.: “Managing the sensitized intestinal

transplant patient and the positive cross-match after transplantation.” Paper presented at the
XIV International Small Bowel Transplant Symposium, Buenos Aires, Argentina, 2015.
37. Sigurdsson L, Reyes J, Todo S, et al.: “Anatomic variability of rejection in intestinal
allografts after pediatric intestinal transplantation.” J Pediatr Gastroenterol Nutr 1998; 27:
403-406.
38. Kato T, Gaynor JJ, Nishida S, et al.: “Zoom endoscopic monitoring of small bowel
allograft rejection.” Surg Endosc 2006; 20: 773-782.
39. Lauro A, Altimari A, Di Simone M, et al.: “Acute cellular rejection monitoring after
intestinal transplant: utility of serologic markers and zoom videoendoscopy as support of
conventional biopsy and clinical findings.” Transplant Proc. 2008 ;40:1575-1576.

40. Lauro A, Pinna AD, Pellegrini S, et al.: “Long-term endoscopic follow-up in small bowel
transplant recipients: single-center series.” Transplant Proc. 2014 ;46:2325-2328.
41. O’Keefe SJ, El Hajj II , Wu T, et al.: “ Endoscopic Evaluation of Small Intestine
Transplant Grafts.” Transplantation 2012;94: 757-762.

ACKNOWLEDGEMENTS: We wish to thank Ms. Claudia Cirillo for her English language
editing of our text.

FINANCIAL SUPPORT AND SPONSORSHIP : none

CONFLICTS OF INTEREST: none

****

